Literature DB >> 16011586

Thromboelastography measurements of whole blood from factor VIII-deficient mice supplemented with rFVIII.

K A Landskroner1, N C Olson, G J Jesmok.   

Abstract

The rotational thromboelastography (ROTEG) assay system allows the real-time analysis of clot formation (fibrin formation) in a whole-blood assay format. The ROTEG system provides significant advantages over the current plasma-based assay systems as it includes the important interactions between cellular and plasmatic coagulation factors. We have employed the ROTEG system to characterize clot formation dynamics in factor VIII- deficient mouse whole blood and examined the ability of recombinant FVIII (rFVIII) supplementation to restore the normal phenotype. The ability to generate a clear dose-response relationship by adding rFVIII to FVIII-deficient murine whole blood (FVIII-/-) demonstrates the feasibility of this approach. A dose-response from 1 U to 0.00001 U mL(-1) demonstrates the enhanced sensitivity of the ROTEG system. Further characterization of this experimental approach may provide a potential tool for comparing the activity of FVIII concentrates and/or evaluating FVIII mutants.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16011586     DOI: 10.1111/j.1365-2516.2005.01104.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  6 in total

1.  An accompanying genetic severe deficiency of tissue factor protects mice with a protein C deficiency from lethal endotoxemia.

Authors:  Francis J Castellino; Deborah L Donahue; Rudolph M Navari; Victoria A Ploplis; Mark Walsh
Journal:  Blood       Date:  2010-09-21       Impact factor: 22.113

2.  Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots.

Authors:  Michael Neyman; Jamie Gewirtz; Mortimer Poncz
Journal:  Blood       Date:  2008-06-16       Impact factor: 22.113

Review 3.  Optimal management of the critically ill: anaesthesia, monitoring, data capture, and point-of-care technological practices in ovine models of critical care.

Authors:  Saul Chemonges; Kiran Shekar; John-Paul Tung; Kimble R Dunster; Sara Diab; David Platts; Ryan P Watts; Shaun D Gregory; Samuel Foley; Gabriela Simonova; Charles McDonald; Rylan Hayes; Judith Bellpart; Daniel Timms; Michelle Chew; Yoke L Fung; Michael Toon; Marc O Maybauer; John F Fraser
Journal:  Biomed Res Int       Date:  2014-03-25       Impact factor: 3.411

4.  Mice deficient in the anti-haemophilic coagulation factor VIII show increased von Willebrand factor plasma levels.

Authors:  Klytaimnistra Kiouptsi; Alexandra Grill; Amrit Mann; Mareike Döhrmann; Maren Lillich; Sven Jäckel; Frano Malinarich; Henning Formes; Davit Manukyan; Saravanan Subramaniam; Avinash Khandagale; Cornelia Karwot; Serge C Thal; Markus Bosmann; Inge Scharrer; Kerstin Jurk; Christoph Reinhardt
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

5.  Global coagulation assays in hemophilia A: A comparison to conventional assays.

Authors:  Saman Aghighi; Anne Riddell; Christine A Lee; Simon A Brown; Edward Tuddenham; Pratima Chowdary
Journal:  Res Pract Thromb Haemost       Date:  2019-12-29

6.  Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B.

Authors:  Barbara Dietrich; Alexandra Schiviz; Werner Hoellriegl; Frank Horling; Karima Benamara; Hanspeter Rottensteiner; Peter L Turecek; Hans Peter Schwarz; Friedrich Scheiflinger; Eva-Maria Muchitsch
Journal:  Int J Hematol       Date:  2013-09-24       Impact factor: 2.490

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.